Metastases Directed Therapy for Oligometastatic Breast Cancer

This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either undergo loco-regional management of the primary tumor or not

NCT Number	NCT06144346
Lead Sponsor	National Cancer Institute, Egypt
Conditions	Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer
Enrollment	150 participants
Start Date	2023-09-20
Primary Completion	2025-08-19 (estimated)
Study Completion	2028-09-20 (estimated)
Updated on ClinicalTrials.gov	2023-11-22